Pfizer licenses CAR-T therapies from China's Starna in up to $2.6B dealPfizer struck an exclusive licensing agreement with Starna Therapeutics to develop three in vivo CAR-T therapies for autoimmune diseases, in a deal worth up to $2.6 billion.Nov 18, 2026·2 sourcesCAR T-cell therapyAutoimmune disease treatmentsCorporate strategyPharmaceutical IndustryDrug developmentImmunotherapyBiotechnology00